1AD
Delivery · High$11M1mo
Adalta
Biotechnology · Fibrosis
Clinical-stage biotech using its proprietary i-body platform (inspired by shark antibody domains) to develop therapeutics for fibrotic diseases and cancer, with lead candidate AD-214 in Phase 1 for IPF.
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.8M
Mar 2026 4C
Runway
1moCRITICAL
Based on Mar 2026 4C
Market Cap
$11M
Burn Rate
$1.9M/qtr
Mar 2026 4C
Shares Outstanding
3.2B
Pipeline Assets
4
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther24 May 2026
Prospectus
AdAlta has lodged a prospectus with ASIC for an offer of options (ASX:1ADO) to sophisticated and professional investors who participated in a $2.5 million placement announced on 4 May 2026. Participants can apply for one option per three shares subscribed, with lead manager 62 Capital receiving 168.75 million options as fee consideration. Shareholder approval is required at an EGM scheduled for 15 June 2026.
3M Price
1AD.ASX$0.004-12.5% 3M
Low $0.004High $0.005
Capital Raises & Buybacks
12mo dilution 19.7%12mo $3M1 raise
Current shares outstanding: 3.2B
Placement
2026-05-04placement
$2.5M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
R&D Tax Incentive
$0.2M received43.5% ATO refund
FY2026received
Auto-extracted from 4C (2026-03-31)
$0.15M
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as or are forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Catalysts (9)· 5 upcoming · 4 past
ConfirmedremoveMed15 June 2026
Related activity
24 May 2026 · ProspectusAdCella additional CAR-T in-licensing agreements
UpcomingExpectedremoveMed30 Sept 2026
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High83/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High88/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 4 of 4 guided dates· rolling 2yr· of 9 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 12% quarterly variation — consistent spend
·
Proposed issue of securities - 1AD — Delivered on time
·
$2.5m placement — Delivered on time
·
BZDS1901 FDA — Regulatory advisors appointed for BZDS1901 — Delivered on time
·
Prospectus — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (4/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓Proposed issue of securities - 1AD
On time
✓$2.5m placement
On time
✓BZDS1901 FDA — Regulatory advisors appointed for BZDS1901— AdAlta has engaged Dark Horse Consulting Group to support pre-IND meeting preparation with the US FDA for its BZDS1901 CAR-T cell therapy, aiming to align manufacturing and clinical trial plans with FDA expectations. The engagement also includes evaluating potential accelerated regulatory designations and expedited pathways for this rare cancer treatment.
On time
✓Prospectus— AdAlta has lodged a prospectus with ASIC for an offer of options (ASX:1ADO) to sophisticated and professional investors who participated in a $2.5 million placement announced on 4 May 2026. Participants can apply for one option per three shares subscribed, with lead manager 62 Capital receiving 168.75 million options as fee consideration. Shareholder approval is required at an EGM scheduled for 15 June 2026.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
No active trials
Announcements(20)
verified
RegulatoryPSauto_awesome
Regulatory advisors appointed for BZDS190124 May 2026
expand_more248KB